Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22057IDB-ST

Select Item

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

The Community-acquired Pneumonia Drugs in Development market research report provides an in-depth analysis of the Community-acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community-Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Community-acquired Pneumonia Pipeline Drugs Market Targets

The targets of the Community-acquired Pneumonia pipeline drugs market are 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein, DNA Gyrase, DNA Topoisomerase IV, 30S Ribosomal Subunit, Complement C5, Gelsolin, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, and Penicillin Binding Protein 2a.

Community-acquired Pneumonia Pipeline Drugs Market, By Targets

Community-acquired Pneumonia Pipeline Drugs Market, By Targets

For more target insights, download a free report sample

Mechanisms of Action of Community-Acquired Pneumonia Pipeline Drugs Market

The mechanisms of action of the Community-acquired Pneumonia pipeline drugs market are 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 30S Ribosomal Subunit Inhibitor, Complement C5 Inhibitor, Gelsolin Replacement, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, and Penicillin Binding Protein 2a Inhibitor.

Community-acquired Pneumonia Pipeline Drugs Market, By Mechanisms of Action

Community-acquired Pneumonia Pipeline Drugs Market, By Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Community-Acquired Pneumonia Pipeline Drugs Market

The routes of administration in the Community-acquired Pneumonia pipeline drugs market are intravenous, oral, inhalational, ophthalmic, and parenteral.

Community-acquired Pneumonia Pipeline Drugs Market, By Routes of Administration

Community-acquired Pneumonia Pipeline Drugs Market, By Routes of Administration

For more routes of administration insights, download a free report sample

Molecule Types in Community-Acquired Pneumonia Pipeline Drugs Market

The molecule types in the Community-acquired Pneumonia pipeline drugs market are small molecule, antibody, recombinant protein, cell therapy, monoclonal antibody, and protein.

Community-acquired Pneumonia Pipeline Drugs Market, By Molecule Types

Community-acquired Pneumonia Pipeline Drugs Market, By Molecule Types

For more molecule type insights, download a free report sample

Key Community-Acquired Pneumonia Pipeline Drugs Market Companies

Some of the key companies in the Community-acquired Pneumonia pipeline drugs market are Iterum Therapeutics Plc, La Jolla Pharmaceutical Company, Paratek Pharmaceuticals Inc, TaiGen Biotechnology Co Ltd, Takeda Pharmaceutical Co Ltd, Wockhardt Ltd, Beijing FuKangren Bio-pharm Tech Co Ltd, BioAegis Therapeutics Inc, Biotest AG, and Eagle Pharmaceuticals Inc.

Community-acquired Pneumonia Pipeline Drugs Market, By Key Companies

Community-acquired Pneumonia Pipeline Drugs Market, By Key Companies

To know more about key companies, download a free report sample

Market report overview

Targets 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein, DNA Gyrase, DNA Topoisomerase IV, 30S Ribosomal Subunit, Complement C5, Gelsolin, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, and Penicillin Binding Protein 2a
Mechanisms of Action 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 30S Ribosomal Subunit Inhibitor, Complement C5 Inhibitor, Gelsolin Replacement, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, and Penicillin Binding Protein 2a Inhibitor
Routes of Administration Intravenous, Oral, Inhalational, Ophthalmic, and Parenteral
Molecule Types Small Molecule, Antibody, Recombinant Protein, Cell Therapy, Monoclonal Antibody, and Protein
Key Companies Iterum Therapeutics Plc, La Jolla Pharmaceutical Company, Paratek Pharmaceuticals Inc, TaiGen Biotechnology Co Ltd, Takeda Pharmaceutical Co Ltd, Wockhardt Ltd, Beijing FuKangren Bio-pharm Tech Co Ltd, BioAegis Therapeutics Inc, Biotest AG, and Eagle Pharmaceuticals Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Community-acquired Pneumonia (Infectious Disease).
  • Reviews of pipeline therapeutics for Community-acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Community-acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • Evaluation of Community-acquired Pneumonia (Infectious Disease) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Community-acquired Pneumonia (Infectious Disease).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Identify and understand the targeted therapy areas and indications for Community-acquired Pneumonia (Infectious Disease). Identify the use of drugs for target identification and drug repurposing.

  • Identify potential new clients or partners in the target demographic.

  • Develop strategic initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.

  • Devise corrective measures for pipeline projects by understanding Community-acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Beijing FuKangren Bio-pharm Tech Co Ltd
BioAegis Therapeutics Inc
Biotest AG
Eagle Pharmaceuticals Inc
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
InflaRx NV
ioGenetics Inc
Iterum Therapeutics Plc
Korea Pharma Co Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Community Acquired Pneumonia – Overview

Community Acquired Pneumonia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Community Acquired Pneumonia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Community Acquired Pneumonia – Companies Involved in Therapeutics Development

Beijing FuKangren Bio-pharm Tech Co Ltd

BioAegis Therapeutics Inc

Biotest AG

Eagle Pharmaceuticals Inc

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

InflaRx NV

ioGenetics Inc

Iterum Therapeutics Plc

Korea Pharma Co Ltd

La Jolla Pharmaceutical Company

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Nabriva Therapeutics Plc

Paratek Pharmaceuticals Inc

ProThera Biologics Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

Wockhardt Ltd

Community Acquired Pneumonia – Drug Profiles

BT-588 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CAL-02 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ceftaroline fosamil – Drug Profile

Product Description

Mechanism Of Action

History of Events

ceftriamidine sodium – Drug Profile

Product Description

Mechanism Of Action

Cx-611 – Drug Profile

Product Description

Mechanism Of Action

History of Events

DBAF-301 – Drug Profile

Product Description

Mechanism Of Action

eravacycline dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

interferon alfa-2b – Drug Profile

Product Description

Mechanism Of Action

KP-091 – Drug Profile

Product Description

Mechanism Of Action

lefamulin acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

nafithromycin – Drug Profile

Product Description

Mechanism Of Action

History of Events

nemonoxacin – Drug Profile

Product Description

Mechanism Of Action

History of Events

omadacycline tosylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

oxytetracycline hydrochloride – Drug Profile

Product Description

Mechanism Of Action

Proteins for Community Acquired Pneumonia – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Plasma Gelsolin Replacement for Infectious Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

solithromycin – Drug Profile

Product Description

Mechanism Of Action

History of Events

sulopenem – Drug Profile

Product Description

Mechanism Of Action

History of Events

sulopenem etzadroxil – Drug Profile

Product Description

Mechanism Of Action

History of Events

tebipenem pivoxil hydrobromide – Drug Profile

Product Description

Mechanism Of Action

History of Events

vilobelimab – Drug Profile

Product Description

Mechanism Of Action

Community Acquired Pneumonia – Dormant Projects

Community Acquired Pneumonia – Discontinued Products

Community Acquired Pneumonia – Product Development Milestones

Featured News & Press Releases

Dec 16, 2021: China’s National Medical Products Administration approves NUZYRA (omadacycline) for the treatment of bacterial pneumonia and skin infections

Nov 29, 2021: Lefamulin NDA filed in Mainland China for treatment of Community Acquired Pneumonia

Oct 04, 2021: Nabriva publishes data demonstrating the potent anti-inflammatory properties of XENLETA (lefamulin)

Sep 24, 2021: Nabriva Therapeutics to present data at IDWeek 2021

Sep 09, 2021: Nabriva and Vizient enter into agreement to make XENLETA (lefamulin) available to Vizient’s Pharmacy Network Program

Sep 08, 2021: Lefamulin receives approval in Taiwan for treatment of community-acquired pneumonia

Aug 26, 2021: Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin

Aug 05, 2021: Everest Medicines announces approval of clinical trial application by China NMPA for Phase 3 trial of Xerava for Community-Acquired Bacterial Pneumonia

Jun 01, 2021: Paratek Pharmaceuticals announces FDA approval of NUZYRA (omadacycline) oral only dosing regimen for the treatment of Community-Acquired Bacterial Pneumonia (CABP)

May 25, 2021: Sinovant Sciences and Nabriva Therapeutics announce positive topline results from phase 3 trial of Lefamulin in Chinese adults with community acquired bacterial pneumonia (CABP)

Mar 16, 2021: Nabriva publishes clinical data analysis highlighting benefits of outpatient management of Community Acquired Bacterial Pneumonia (CABP) with oral XENLETA (lefamulin)

Feb 23, 2021: Study demonstrates macrolide-resistance in S. pneumoniae in the United States exceeds 25 percent threshold set in current Community-Acquired Bacterial Pneumonia (CABP) treatment guidelines

Feb 08, 2021: Paratek announces expansion of Nuzyra launch into the community setting

Dec 07, 2020: Nabriva Therapeutics and Sinovant Sciences restructure license agreement for XENLETA for community-acquired bacterial pneumonia in China

Oct 21, 2020: Key highlights include data on NUZYRA as an alternative to standard of care to reduce clostridioides difficile infections and real-world experience with NUZYRA for nontuberculous mycobacterial and MDR/XDR gram negative infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Community Acquired Pneumonia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Community Acquired Pneumonia – Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022

Community Acquired Pneumonia – Pipeline by BioAegis Therapeutics Inc, 2022

Community Acquired Pneumonia – Pipeline by Biotest AG, 2022

Community Acquired Pneumonia – Pipeline by Eagle Pharmaceuticals Inc, 2022

Community Acquired Pneumonia – Pipeline by Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, 2022

Community Acquired Pneumonia – Pipeline by InflaRx NV, 2022

Community Acquired Pneumonia – Pipeline by ioGenetics Inc, 2022

Community Acquired Pneumonia – Pipeline by Iterum Therapeutics Plc, 2022

Community Acquired Pneumonia – Pipeline by Korea Pharma Co Ltd, 2022

Community Acquired Pneumonia – Pipeline by La Jolla Pharmaceutical Company, 2022

Community Acquired Pneumonia – Pipeline by Meiji Seika Pharma Co Ltd, 2022

Community Acquired Pneumonia – Pipeline by Merck & Co Inc, 2022

Community Acquired Pneumonia – Pipeline by Nabriva Therapeutics Plc, 2022

Community Acquired Pneumonia – Pipeline by Paratek Pharmaceuticals Inc, 2022

Community Acquired Pneumonia – Pipeline by ProThera Biologics Inc, 2022

Community Acquired Pneumonia – Pipeline by TaiGen Biotechnology Co Ltd, 2022

Community Acquired Pneumonia – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Community Acquired Pneumonia – Pipeline by Wockhardt Ltd, 2022

Community Acquired Pneumonia – Dormant Projects, 2022

Community Acquired Pneumonia – Dormant Projects, 2022 (Contd..1)

Community Acquired Pneumonia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Community Acquired Pneumonia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more